Migraine Management in Pilots: A Focused Narrative Review for the Treating Neurologist
Headache and Pain Research · 30.06.2026 · 27 (2) · 108-116
DOI: 10.62087/hpr.2026.0019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache and Pain Research, erschienen am 30.06.2026. Verfasst von Chan-Young Park und 4 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Migraine, one of the leading global causes of disability, presents a complex challenge in aviation medicine. Headache is the fourth most common cause of in-flight pilot incapacitation, and cockpit-related exposures—including hypobaric hypoxia, low humidity, circadian disruption, and, in military aviation, sustained +Gz loading—may lower the migraine threshold. At the same time, aeromedical regulations restrict the medication options available to treating neurologists. This focused narrative review synthesizes pilot-specific clinical evidence and the principal regulatory documents issued by the International Civil Aviation Organization (ICAO Annex 1 and Doc 8984) and the U.S. Federal Aviation Administration (FAA Aviation Medical Examiner Guide) to provide neurologists with a practical framework for managing pilots with migraine. Simple analgesics, including acetaminophen/paracetamol, ibuprofen, naproxen, and aspirin at standard doses, are permitted under both ICAO and FAA frameworks. Triptans are permitted by the FAA after a 24- to 48-hour ground-observation period, whereas gepants such as ubrogepant and rimegepant require a 48-hour observation period. Beta-adrenergic blockers and calcium channel blockers are accepted preventive agents under both frameworks after a 7-day ground trial, whereas tricyclic antidepressants, topiramate, valproate, opioids, and butalbital-containing compounds are unacceptable. Anti–calcitonin gene-related peptide monoclonal antibodies are now accepted by the FAA after a 7-day ground trial, providing an additional certification-compatible option for pilots with migraine refractory to traditional preventive therapy. Most pilots with migraine can be managed in a manner compatible with continued flight duty when the neurologist selects medications within the applicable aeromedical formulary and documents clinical stability objectively to support certification.
Zitieren
APA
Park, C., Kang, D., Lim, H., Jeong, H., & Park, K. (2026). Migraine Management in Pilots: A Focused Narrative Review for the Treating Neurologist. Headache and Pain Research, 27(2), 108-116. https://doi.org/10.62087/hpr.2026.0019
Vancouver
Park C, Kang D, Lim H, Jeong H, Park K. Migraine Management in Pilots: A Focused Narrative Review for the Treating Neurologist. Headache and Pain Research. 2026;27(2):108-116. doi:10.62087/hpr.2026.0019
BibTeX
@article{Park2026,
author = {Park, Chan-Young and Kang, Dongwook and Lim, Heejung and Jeong, Hae-Bong and Park, Kwang-Yeol},
title = {Migraine Management in Pilots: A Focused Narrative Review for the Treating Neurologist},
journal = {Headache and Pain Research},
year = {2026},
volume = {27},
number = {2},
pages = {108--116},
doi = {10.62087/hpr.2026.0019}
}
EUVIMED